Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth-Ayerst Acel-Imune

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Company is discontinuing its diphtheria, tetanus and acellular pertussis vaccine Acel-Imune. Wyeth made the decision after reviewing its product portfolio, production capabilities and the recent consent decree with FDA over violations of good manufacturing practices. Acel-Imune was manufactured at one of the two facilities affected by the consent decree. Acel-Imune and its tetanus toxoids "generated minimal revenue and income," the company said. Sales for the combination were $71 mil. in 2000. Acel-Imune was the leading DTaP vaccine with a 45% share of the $86.3 mil. market for the 12-month period ended in November, according to IMS Health dat

You may also be interested in...



Akorn Defaults On Loan Agreement After Sale Bid Falls Flat

Facing soaring legal costs stemming from its failed merger with Fresenius Kabi and burdened by substantial debt, Akorn elected to put itself up for sale earlier this year in order to help repay lenders. But the company has now defaulted on an agreement with its creditors after no bidder stepped up to the plate.

Pipeline Watch: Vericiguat, Evinacumab Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

EMA Set To Discuss Safety Of Ranitidine

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

Topics

UsernamePublicRestriction

Register

PS001380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel